Elicio Therapeutics, formerly Vedantra, is a cancer vaccine company developing a novel lymph-node targeting platform to treat solid tumors. The company’s proprietary Amphiphile Vaccine (“Amph-vaccine”) technology stimulates the body’s own immune cells to attack cancerous tissues. We believe the Amphiphile could potentially facilitate best-in-class T-cell activation against cancer cells. Based on strong preclinical animal data we are working on two cancer immunotherapy development programs for human papilloma virus (HPV) and K- Ras tumors.
OcuTerra Therapeutics, Inc. formerly known as SciFluor Life Sciences, Inc. is an ophthalmology company focused on treating eye diseases with innovative new products. The company is developing OTT166 (formerly known as SF0166), a potentially revolutionary product for the treatment of diabetic retinopathy ("DR"), a disease affecting the back of the eye that is increasingly prevalent in the global diabetes epidemic. The current standard of treatment for DR requires the patient to receive an injection into the retina, while OTT166 is designed to be administered in the form of eye drops.
Aardvark Therapeutics is developing a first-in-class oral drug (ARD-101) for metabolic diseases and hyperphagia, and also has an important additional pathway in NASH and other inflammatory indications. The company has completed Phase 1a and 1b studies and will initiate Phase 2 studies in the second half of 2021 in at least three clinical indications: Prader-Willi syndrome, general obesity, post-bariatric surgery patients with refractory weight gain, NASH (non-alcoholic steatohepatitis or "fatty liver" disease) and IBD (irritable bowel disease).
Atai Life Sciences is a venture-backed biotech platform focused on psychedelic molecules for various indications such as depression, anxiety, addiction and post-traumatic stress disorder. The company does not own the assets outright but takes majority stakes in companies developing psychedelic molecules. It currently has majority stakes in 11 companies. The company's founders are different from the usual founders of biotech companies, and created the company to develop psychedelic molecules that, in their opinion, better serve patients coping with the aforementioned conditions than with traditional medications.
Elucida Oncology's innovative C'Dot platform enables precise tumor targeting, deep tumor penetration and increased efficacy in tumor elimination. It enables the production of new therapies that are rapidly and efficiently eliminated from the body, reducing the potential for off-target toxicities and resulting in an improved safety profile for patients. The ability of the ultra-small particle platform to target or safely remove cancer cells from the body, primarily through the renal system, offers the potential for a game-changer in the diagnosis and treatment of solid primary tumors and metastatic cancers.
Astrocyte Pharmaceuticals is dedicated to clinically testing the neuroprotective benefits of selective astrocyte activation, and to promoting innovative therapeutic agents for the treatment of brain-injured patients. Their innovative strategy protects and repairs damaged neurons by selective stimulation of astrocytes. This enables the selective activation of their care processes, including the elimination of harmful extracellular molecules and the restoration of ionic homeostasis.